Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

e to research and development. This compares to operating expenses of $19.6 million and research and development expenses of $17.6 million for the same nine month period last year. The Company reported a net loss for the nine months ended September 30, 2007 of $15.2 million compared to a net loss of $12.2 million for the same period last year.

TorreyPines merged with Axonyx Inc. on October 3, 2006. The Company's financial statements reflect the historical results of TorreyPines prior to the merger and that of the combined company following the merger, and do not include the historical results of Axonyx Inc. prior to the completion of the merger.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer's disease. Further information is available at http://www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for tezampanel as a treatment for migraine, the potential timing, development and initiation of Phase III clinical trials of tezampanel, the potential for NGX267 to treat the symptoms of cognitive impairment associated with schizophrenia and the potential for NGX267 to treat dry mouth, or xerostomia. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPin
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... DE (PRWEB) June 18, 2013 DuPont ... to the 11th annual DuPont National AgriScience Teachers Ambassador ... Farms in Chestertown, Md. , The ... by DuPont and is a special project of the ... Association of Agricultural Educators (NAAE) . The highly ...
(Date:6/18/2013)... , June 18, 2013  regulated information — ... Jeff Klauk today announced the launch of a ... loved ones. The Pledge empowers ... a stand and make a personal commitment to demand ... their health care team and additional partial-onset seizure control.  ...
(Date:6/18/2013)... Israel , June 18, 2013 ... Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished ... that the company has been granted a United ... the US and Europe for the ... number 8,410,176 B2 is titled Intermediate Compounds and Processes ...
(Date:6/18/2013)... , June 18, 2013 ... ) has announced the addition of the ... [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & ... & Auto Injectors] & Therapeutics [Diabetes & ... report to their offering.      ...
Breaking Biology Technology:DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 2Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 3Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 4Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 5Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy 6Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 2Injectable Drug Delivery Market by Formulations, Devices & Therapeutics - Global Forecasts to 2017 3
... LOS ANGELES, Dec. 6, 2010 Todd Hutchings has ... Sciences Practice Group.  Peter Levin, who led the practice, ... role recruiting CEOs and C-Level executives. In ... deepening core client relationships, working with boards and providing ...
... kind of fiber that could be tougher than Kevlar. ... from other universities and the MER Corporation, Horacio Espinosa, ... & Entrepreneurship at the McCormick School of Engineering and ... performance fiber from carbon nanotubes and a polymer that ...
... 2010 Baylor Research Institute (BRI), the research arm ... formed a three-year partnership with Roche (SIX: RO, ROG; ... human immunology platforms developed at the Baylor Institute for ... These programs will leverage BIIR,s leading position in human ...
Cached Biology Technology:Egon Zehnder International Names Todd Hutchings to Lead Life Sciences Practice Group 2Researchers create new high-performance fiber 2Researchers create new high-performance fiber 3Roche, Baylor Research Institute Partner in Human Immunology Research 2
(Date:6/19/2013)... the most potent physiological anabolic agent for tissue-building ... of lipids, protein and carbohydrates, and inhibiting their ... also plays a major role in stimulating glucose ... metabolized and removed from the blood following meals. ... mechanisms by which insulin regulates glucose uptake in ...
(Date:6/19/2013)... University study offers further proof that the divergence of ... years ago was profoundly influenced by mutations to DNA ... off. , The study, published June 9 in ... that regulation of genes must play an important role ... and chimps in the proteins produced by genes. Indeed, ...
(Date:6/18/2013)...  Paris Air Show – Marvin Test ... a leading provider of innovative test solutions for ... solutions this week at the Paris Air ... including increasingly complex armament systems with longer lifecycles, ... test solutions that address legacy system obsolescence. Marvin ...
Breaking Biology News(10 mins):Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3
... Estimates of whale population size based on genetics ... fully understand the ecological implications of the large-scale commercial ... a comparison of DNA samples from modern and prehistoric ... substantially larger pre-whaling and saw a sharp, recent decrease ...
... across the country will assemble at the U.S. Department ... May 17, and Friday, May 18, for the third ... Control of Plasma Kinetics. The Laboratory is located on ... The DOE-funded center was launched with a five-year grant ...
... This press release is available in ... will be granted more,autonomy and far more freedom of ... Further Development,Act, as a result of which KIT will ... employees in the future. In,addition, KIT will have the ...
Cached Biology News:Whale population size, dynamics determined based on ancient DNA 2More freedom of discretion for KIT 2
... UniPrimer-fluorescein is a hairpin primer labeled ... (fluorescein and non-fluorescent quencher) and a ... UniPrimer is identical to the UniPrimer ... System (S7901) and is provided at ...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... The Rotofor purification system with PowerPac 3000 ... protein separation and purification by liquid-phase isoelectric ... mini (18 ml) and standard (60 ml) ... electrode chambers, PowerPac 3000 power supply, 10 ...
Recognizes Human Connexin 45. Due to sequence homologies, this antibody is also expected to react with canine (100% homology) and mouse (92% homology) Connexin 45. Also confirmed to work on rat C6 c...
Biology Products: